AIM:To observe the clinical effect and safety of mitomycin C(MMC)applied to nasal endoscopic dacryocystorhinostomy for chronic dacryocystitis.

METHODS:Selecting 297 patients(328 eyes)who were diagnosed as chronic dacryocystitis from July 2012 to June 2015 in our hospital, in which 266 patients were monocular and 31 were binocular. And then dividing them into two groups, 166 patients(166 eyes)in treatment group,and there were 162 patients(162 eyes)in control group. If the patient was binocular, each eye was selected in treatment group or control group randomly. The surgical procedures of nasal endoscopic dacryocystorhinostomy combined with nasolacrimal duct stent placement, were used in both groups, and MMC with the concentration of 0.2mg/mL was applied topically to the treatment group, while the control group was treated without MMC. All cases were followed up for 3 to 36mo, observed for clinical effect and safety.

RESULTS:One hundred and twenty-one eyes were cured, 37 were improved and 8 were failed in the treatment group of 166 eyes, total effective rate was 95.18%. While in the control group, 103 eyes were cured, 36 were improved and 23 were failed in 162 eyes, total effective rate was 85.80%. The difference between the two groups was statistically significant(P<0.05).

CONCLUSION: MMC applied to nasal endoscopic dacryocystorhinostomy for chronic dacryocystitis allows less tissue injury, effectively reduces cicatricial adhesion and hyperplasia of granulation tissue after operations on nasal cavity and enhance the success rate of the operations, which is a simple, safe and effective treatment.